Sponsors / MIRM
MIRM

Mirum Pharmaceuticals, Inc.

Company identity checked against sources

See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.

Follow company
19Trials in this database
13Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic AcidNCT00007020MIRMPhase 3Completed2009-12Actual
Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid SynthesisNCT01115582MIRMPhase 3Completed2010-08Actual
Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid SynthesisNCT01438411MIRMPhase 3Completed2016-07Actual
Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic CholestasisNCT02057718MIRMPhase 2Completed2020-05-08Actual
A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)NCT03905330MIRMPhase 3Completed2022-09-01Actual
MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat StudyNCT04168385MIRMPhase 2Completed2024-09-04Actual
An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)NCT04185363MIRMPhase 3Completed2025-04-23Actual
Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)NCT04270682MIRMPhase 3Completed2023-07-13Actual
Evaluation of Maralixibat in Biliary Atresia Response Post-KasaiNCT04524390MIRMPhase 2Completed2023-11-07Actual
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)NCT04663308MIRMPhase 2Active not recruiting2026-02-20Actual
A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)NCT04718961MIRMPhase 2Terminated2022-12-07Actual
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).NCT04729751MIRMPhase 2Completed2024-12-17Actual
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary CholangitisNCT05050136MIRMPhase 2Active not recruiting2027-01Estimated
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)NCT06553768MIRMPhase 3Active not recruiting2026-10Estimated
A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta InfectionNCT06907290MIRMPhase 2, Phase 3Active not recruiting2029-05Estimated
A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)NCT07200908MIRMPhase 3Recruiting2027-06-30Estimated
Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)NCT07209462MIRMPhase 2Recruiting2027-10Estimated
A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)NCT07298330MIRMPhase 3Active not recruiting2026-08Estimated
Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving BulevirtideNCT07454837MIRMPhase 2, Phase 3Recruiting2027-08-31Estimated

Latest recorded trial changes

An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

NCT04185363 · Mirum Pharmaceuticals, Inc.

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Incidence of Treatment Emergent Adverse Events (TEAEs) during the study

+ Updated value

measure: Mean Change From Baseline Over Time in the Average Morning ItchRO(Obs) Severity Score

Check registry source · The saved outcome text may be shortened. Check the source for full wording.
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).

NCT04729751 · Mirum Pharmaceuticals, Inc.

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Frequency of treatment-emergent adverse events [TEAEs]

+ Updated value

measure: Frequency of Treatment-emergent Adverse Events [TEAEs]

Check registry source · The saved outcome text may be shortened. Check the source for full wording.